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A B S T R A C T
Recovery from hepatitis B virus (HBV) infection is
associated with the presence of antibodies against
HBV surface (HBs) antigen and HBV core (HBc)
antigen. However, anti-HBs antibodies are lost in
many cases, and only anti-HBc antibodies persist.
A higher frequency of the anti-HBc-alone pattern
has been demonstrated for anti-hepatitis C virus
(HCV)-positive patients. In this report, 1126 anti-
HCV-positive ⁄ anti-HBc-positive patients were
studied, and the role of HCV replication in
influencing the presence or absence of anti-HBs
antibodies was investigated. The anti-HBc-alone
phenotype was significantly more frequent in
HCV-viraemic than in HCV-recovered patients.
This finding represents new information regard-
ing the immunopathogenesis of chronic HCV
infection and supports previous data indicating
impaired humoral immune responses in HCV
infection.
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The presence of antibodies against both hepatitis
B virus (HBV) surface antigen (HBsAg) and HBV
core antigen (HBcAg) are serological markers of
recovery from HBV infection. However, in many
cases, anti-HBc, but no anti-HBs, antibodies can
be detected. The clinical relevance of this phe-
nomenon is controversial, and the mechanisms
responsible for the loss of anti-HBs antibodies are
not known. Previously, it has been shown that
subjects with antibodies only to HBV core (anti-
HBc alone) were more often co-infected with
hepatitis C virus (HCV) than subjects who also
had antibodies to HBsAg in addition to HBcAg
[1]. Recently, Greub and Frei reported a 30%
frequency of the anti-HBc-alone pattern among
anti-HBc- ⁄ anti-HCV-positive patients [2]. How-
ever, about 20% of the anti-HCV-positive patients
tested in routine diagnostic laboratories are neg-
ative for HCV RNA in serum, indicating recovery
from HCV infection. The earlier studies investi-
gating patients with antibodies against HBV core
alone did not distinguish between HCV-viraemic
and HCV RNA-negative patients [1,2]. Since it is
not known whether active HCV replication is
associated with the anti-HBc-alone phenotype in
anti-HCV-positive subjects, the present study
addressed this issue in 1126 anti-HCV-positive
and anti-HBc-positive individuals.
In total, 3153 consecutive anti-HCV-positive
sera collected from patients between 1992 and
2001 at the Hannover Medical School, Germany
were investigated for serological markers of
ongoing or previous HBV infection. All patients
tested positive for anti-HCV in the Laboratory of
Gastroenterology and Hepatology. Patients com-
prised inpatients admitted to Hannover Medical
School and outpatients seen in the clinic of our
department. Patients with HIV co-infection were
excluded from the analysis. None of the patients
was tested while receiving antiviral treatment.
Routine serological markers for hepatitis
viruses consisted of anti-hepatitis A virus IgG,
anti-HBs, anti-HBc, HBsAg, anti-HCV and anti-
hepatitis D virus. Serological testing was done as
described previously with commercial immuno-
enzymatic assays (Abbott Laboratories, Chicago,
IL, USA) [3,4]. Anti-HCV was tested from 1992 on
by the second-generation assay, and then after
1995 by the third-generation assay. Detection and
quantification of HCV RNA, as well as HCV
genotyping, was also performed exactly as des-
cribed previously [5,6].
Sixty-eight patients underwent liver biopsy. The
liver biopsy material was fixed in formalin and
embedded in paraffin for routine staining with
haematoxylin and eosin. The biopsy material was
examined by a single experienced pathologist, who
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was unaware of the clinical and virological data.
Biopsy specimens were assessed for fibrosis (sta-
ging, score 0–6) and activity (grading, score 0–18)
according to the hepatitis activity index of Knodell
and co-workers, as modified by Ishak et al. [7].
In total, 1126 anti-HCV-positive individuals
were identified who also tested positive for anti-
HBc antibodies in the absence of HBsAg. HCV
RNA was detectable by PCR (detection limit 600
copies ⁄mL) in 887 (79%) of these patients. As
expected for German patients, the dominant HCV
genotype was genotype 1 (303 of 426 sera tested;
71%). Antibodies against both HBsAg and
HBcAg were found in 881 (79%) patients, while
the anti-HBc-alone phenotype was present in 245
(21%) individuals. This frequency is about one-
third lower than that found by Greub and Frei [2].
It can be speculated that a different proportion of
patients with additional risk factors, e.g., intra-
venous drug abuse or haemodialysis, might have
contributed to the higher number of patients
lacking anti-HBs in that study. In addition, gen-
etic factors could potentially contribute to the
ability of patients to produce anti-HBs antibodies.
Importantly, the anti-HBc-alone pattern was
found significantly more often in HCV-viraemic
patients (214 of 887; 22%) than in HCV RNA-
negative individuals (31 of 249; 13%; p < 0.0001).
In addition, among anti-HBs-positive ⁄HCV RNA-
viraemic patients, HCV RNA levels, as investi-
gated by Cobas Amplicor, tended to be higher in
patients with anti-HBs titres < 50 IU ⁄mL than in
patients with anti-HBs titres > 50 IU ⁄mL (p ¼
0.12, data not shown). In contrast, no significant
association was evident between the anti-HBc-
alone antibody phenotype and HCV genotypes,
age, sex, previous exposure to hepatitis A virus,
liver function tests or histological grading and
staging (Table 1).
Thus, active HCV replication was associated
with decreased anti-HBs antibody production in
HBcAg-positive ⁄HBsAg-negative patients. The
present data are in line with previous reports
of impaired humoral immune responses after
vaccination against HBV or hepatitis A virus in
patients with chronic HCV infection [8,9].
What could be the explanation for these obser-
vations? First, humoral and cellular immune
responses are induced by activation of dendritic
cells. This cell type has been shown to be
functionally impaired in chronic HCV infection,
but not after recovery from HCV infection [10,11].
Second, HCV replication is associated with
decreased HBV replication [12]. Thus, some of
the patients might not have recovered totally from
HBV infection, but HBV could instead have been
suppressed by HCV co-infection. In this scenario,
latent ongoing chronic HBV infection could be the
reason for undetectable anti-HBs antibodies that
are captured by low levels of HBsAg. Finally,
cellular immune responses against HCV might
interfere with HBV-specific B-cell and T-cell
responses. Specific cross-reactivity or non-specific
bystander mechanisms could be involved in
Table 1. Relationship between anti-
body production and other patient
characteristics Anti-HBs
+/anti-HBc+
(n = 881; 79%)
Anti-HBs–/anti-HBc+
(‘anti-HBc alone’)
(n = 245; 21%) p value
HCV RNA positive 76% 87% < 0.001
HCV genotyped (n) 311 115
Genotype 1 70% 75% NS
Genotype 2 ⁄ 3 27% 24% NS
Other genotypes 3% 1% NS
Age (years) 50.4 ± 15.9 52.2 ± 15.4 NS
Female ⁄male 335 ⁄ 546 86 ⁄ 159 NS
ALT (U ⁄L)a 60 ± 57 48 ± 55 NS
AST (U ⁄L)a 38 ± 24 29 ± 24 NS
Bilirubin (mmol ⁄L)a 15.0 ± 12.1 12.6 ± 8.0 NS
Inflammationb 6.7 ± 2.8 5.2 ± 2.7 NS
Fibrosisb 2.8 ± 2.2 3.0 ± 2.5 NS
aLiver functions tests were available for 192 patients.
bHistological grading (inflammatory score 0–18) and staging (fibrosis score 0–6)
was performed according to the Ishak score (11) in 68 patients (56 anti-HBs
positive and 12 anti-HBc alone).
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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suppressing anti-HBs-producing B-lymphocytes.
Alternatively, a stronger anti-HBV humoral
immune response, as indicated by the presence
of anti-HBs antibodies, might in part suppress
HCV replication [13]. Heterologous immunity
and viral interactions are much more frequent
than previously thought, and cross-reactivity
between influenza A virus and HCV determin-
ant-specific cytotoxic T-cells has been described
[14]. The potential clinical relevance of viral
co-infections has been emphasised by reports on
the improved survival of HIV-positive patients
who are co-infected with GB virus C [15].
Future studies will be needed to clarify the
detailed mechanisms by which HCV replication
suppresses anti-HBs production in anti-HBc-pos-
itive patients. Understanding the pathogenesis of
HBV–HCV co-infection is important not only for
hepatologists, but also for virologists in general,
since infection with multiple hepatitis viruses
represents a unique and clinically well defined
model to study viral interactions and heterolo-
gous immunity in humans.
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A B S T R A C T
Resistance to fluoroquinolones has increased
markedly since their introduction. Mechanisms
of resistance to any antibiotic class might play a
role in resistance to an unrelated antibiotic class.
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